A prospective, nonrandomized clinical study of patients with chronic total occlusion lesions (CTO) treated with everolimus-eluting scaffolds: A study of Poznan CTO-Absorb Registry
Latest Information Update: 29 Dec 2017
Price :
$35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- 29 Dec 2017 New trial record
- 02 Nov 2017 Results of subgroup analysis (n=65) presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
- 02 Nov 2017 Results presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.